Wirth P J, Henderson Berg M H, Sadick N
University of Buffalo, Buffalo, NY, USA.
McGill University, Montreal, QC, Canada.
Skin Therapy Lett. 2017 Nov;22(6):5-7.
Approximately 16 million Americans have rosacea, an inflammatory cutaneous disorder with central facial erythema, papules, pustules, telangiectasia, flushing, and swelling being among the more commonly recognized features. Overexpression of cathelicidin peptide LL-37 has been implicated in the pathophysiology of rosacea. Azelaic acid has been found to inhibit the pathologic expression of cathelicidin, as well as the hyperactive protease activity that cleaves cathelicidin into LL-37. Given these findings, a small prospective, open-label, interventional trial was undertaken to assess the effects of azelaic acid 15% gel on inflammatory lesions of papulopustular rosacea in a real-world setting. Use of azelaic acid was associated with a significant reduction in inflammatory lesions, which persisted beyond the active treatment phase. Overall, azelaic acid 15% gel is an appropriate initial topical therapy for the treatment of moderate facial rosacea.
约1600万美国人患有酒渣鼻，这是一种炎症性皮肤疾病，面部中央红斑、丘疹、脓疱、毛细血管扩张、潮红和肿胀是较为常见的特征。抗菌肽LL-37的过表达与酒渣鼻的病理生理学有关。已发现壬二酸可抑制抗菌肽的病理表达，以及将抗菌肽裂解为LL-37的过度活跃的蛋白酶活性。基于这些发现，开展了一项小型前瞻性、开放标签的干预试验，以评估15%壬二酸凝胶在实际应用中对丘疹脓疱型酒渣鼻炎症性皮损的影响。使用壬二酸与炎症性皮损显著减少相关，且这种减少在积极治疗阶段之后仍持续存在。总体而言，15%壬二酸凝胶是治疗中度面部酒渣鼻的合适初始局部治疗方法。
